Ultrasound JVP to Estimate CVP, IV Metoprolol vs Diltiazem for Atrial Fibrillation with RVR, Ischemic Stroke and Bleeding Risk with Apixaban vs Rivaroxaban, Reducing Sleep Interruptions in Hospital, Outpatient Remdesivir, Molnupiravir for COVID-19

It's our last episode in 2021! This episode we have Dr. Libo Wang and Dr. Jon Harrison on to talk about their new paper in the Annals of Internal Medicine about ultrasound JVP for estimating CVP, validated with right heart catheterization. We also ask them their thoughts on a new meta-analysis looking at metoprolol vs diltiazem for atrial fibrillation with RVR.

We also look at a new large retrospective study of apixaban vs rivaroxaban for stroke prevention, a study looking at reducing sleep interruptions in the hospital, and two new outpatient therapies for COVID-19 infection.

Happy New Year!

Ultrasound JVP for estimating CVP

IV Diltiazem vs Metoprolol for A fib with RVR

Major Ischemic and Hemorrhagic Events in Apixaban vs Rivaroxaban for AF

Reducing Sleep Interruptions in Hospitalized Patients

Early Remdesivir for Outpatient COVID-19

Molnupiravir for Outpatient COVID-19












Music from Uppbeat (free for Creators!):

https://uppbeat.io/t/soundroll/dope

License code: NP8HLP5WKGKXFW2R

Music from Uppbeat (free for Creators!):

https://uppbeat.io/t/soundroll/dope

License code: NP8HLP5WKGKXFW2R